TY  - CHAP
M1  - Book, Section
TI  - Hairy Cell Leukemia
A1  - Damon, Lloyd E.
A1  - Andreadis, Charalambos Babis
A2  - Papadakis, Maxine A.
A2  - McPhee, Stephen J.
A2  - Rabow, Michael W.
Y1  - 2021
N1  - 
T2  - Current Medical Diagnosis & Treatment 2021
AB  - Key  Clinical  Updates  in  Hairy  Cell  LeukemiaMoxetumomab  pasudotox  is  a  recombinant  CD22-targeting  immunotoxin  recently  approved  for  patients  with  refractory  hairy  cell  leukemia.  It  has  shown  a  durable  complete  response  rate  of  31%  in  the  pivotal  trial.  
SN  - 
PB  - McGraw-Hill Education
CY  - New York, NY
Y2  - 2023/05/30
UR  - accessmedicine.mhmedical.com/content.aspx?aid=1175800696
ER  -